A medication that doctors have used for years to treat high blood pressure may also help people live longer and age more slowly, according to new research from scientists at the University of Liverpool. The study suggests that the drug, called rilmenidine, could one day become part of a new strategy to promote healthier aging.
Aging is a natural process that affects every part of the body. As people grow older, their cells and tissues slowly lose the ability to repair themselves. This gradual decline increases the risk of many diseases, including heart disease, diabetes, dementia, and cancer.
Because of this, scientists around the world are searching for ways to slow the aging process and help people stay healthier for longer.
For decades, one of the most reliable methods scientists have found to slow aging in animals is caloric restriction. This approach involves reducing daily calorie intake while still providing enough nutrients to keep the body healthy. Studies in many species, including worms, flies, mice, and monkeys, have shown that eating fewer calories can extend lifespan and delay age-related diseases.
However, following a strict low-calorie diet for many years is very difficult for most people. Some individuals who attempt long-term calorie restriction may experience side effects such as fatigue, weakness, or reduced bone density.
Because of these challenges, researchers are increasingly interested in finding medications that can produce similar benefits without requiring major lifestyle changes.
In the new study, scientists from the University of Liverpool investigated whether the blood pressure drug rilmenidine might have effects similar to caloric restriction. The research was led by Professor João Pedro Magalhães, a scientist who studies aging and longevity. The results of the study were published in the scientific journal Aging Cell.
To explore the drug’s effects, the research team studied animals that were given rilmenidine at different stages of life. Some animals received the medication when they were young, while others began taking it later in life. The researchers then observed how long the animals lived and measured several indicators of health and aging.
The results were encouraging. Animals that received rilmenidine lived longer on average than those that did not receive the drug. In addition, the treated animals showed improvements in several biological markers that are linked to healthier aging. These changes were similar to those seen in animals that follow calorie-restricted diets.
The scientists also worked to understand how the drug produces these effects inside the body. Their research showed that rilmenidine acts on a specific receptor in cells known as the I1-imidazoline receptor. This receptor is also known by the name nish-1.
Cell receptors are small structures on the surface of cells that receive signals from chemicals in the body. When a drug activates a receptor, it can trigger a chain of biological reactions inside the cell. In this case, activating the nish-1 receptor appears to influence processes that are connected to aging and cellular health.
The researchers believe that rilmenidine may help cells respond to stress in a way that supports longer life and better health. These protective effects appear to resemble the biological responses that occur during calorie restriction.
One reason scientists are excited about this discovery is that rilmenidine is not an experimental drug. It has already been used for many years to treat high blood pressure in patients. Doctors prescribe it to help relax blood vessels and reduce the pressure that the heart must work against when pumping blood.
Because the drug is already approved for medical use in several countries, researchers have a good understanding of its safety profile. It is taken as a pill and is generally well tolerated. Most patients who use it experience only mild side effects, if any.
This makes rilmenidine very different from many other substances being studied for anti-aging effects. Some experimental treatments are complicated, expensive, or not yet proven safe for humans. In contrast, rilmenidine is already widely available and relatively easy to use.
Professor Magalhães and his team believe that repurposing existing medications could be a promising approach for improving health during aging. Instead of developing entirely new drugs from scratch, scientists may be able to use medicines that are already approved for other conditions.
Even small changes in the aging process could have large benefits for society. Around the world, populations are getting older as life expectancy increases. If researchers can find ways to delay aging slightly, it may help reduce the risk of many diseases that appear later in life.
Healthier aging could mean that people remain active and independent for longer periods of time. It could also reduce the burden on healthcare systems and improve quality of life for millions of older adults.
The researchers stress that much more work is still needed before rilmenidine could be recommended as an anti-aging treatment for people. Future studies will need to examine whether the same effects seen in animals also occur in humans.
Clinical trials will be important to determine the safest doses and to confirm whether the drug can truly slow aging or reduce age-related diseases in people.
Even so, the discovery provides an exciting new direction for the growing field of geroscience, which focuses on understanding and slowing the biological processes of aging.
By studying drugs like rilmenidine, scientists hope to unlock new ways to extend not only how long people live, but also how long they remain healthy.
If you care about blood pressure, please read studies about blood pressure drug that may increase risk of sudden cardiac arrest, and these teas could help reduce high blood pressure.
For more health information, please see recent studies about nutrient that could strongly lower high blood pressure, and results showing this novel antioxidant may help reverse blood vessels aging by 20 years.
Copyright © 2026 Knowridge Science Report. All rights reserved.
